Abstract

Malaria remains a major cause of morbidity and mortality worldwide with 219 million infections and 435,000 deaths predominantly in Africa. The infective Plasmodium sporozoite is the target of a potent humoral immune response that can protect murine, simian and human hosts against challenge by malaria-infected mosquitoes. Early murine studies demonstrated that sporozoites or subunit vaccines based on the sporozoite major surface antigen, the circumsporozoite (CS) protein, elicit antibodies that primarily target the central repeat region of the CS protein. In the current murine studies, using monoclonal antibodies and polyclonal sera obtained following immunization with P. falciparum sporozoites or synthetic repeat peptides, we demonstrate differences in the ability of these antibodies to recognize the major and minor repeats contained in the central repeat region. The biological relevance of these differences in fine specificity was explored using a transgenic P. berghei rodent parasite expressing the P. falciparum CS repeat region. In these in vitro and in vivo studies, we demonstrate that the minor repeat region, comprised of three copies of alternating NANP and NVDP tetramer repeats, contains an epitope recognized by sporozoite-neutralizing antibodies. In contrast, murine monoclonal antibodies specific for the major CS repeats (NANP)n could be isolated from peptide-immunized mice that had limited or no sporozoite-neutralizing activity. These studies highlight the importance of assessing the fine specificity and functions of antirepeat antibodies elicited by P. falciparum CS-based vaccines and suggest that the design of immunogens to increase antibody responses to minor CS repeats may enhance vaccine efficacy.

Highlights

  • The repeat region of the circumsporozoite (CS) protein of all Plasmodium species contains a species-specific immunodominant B cell epitope that is recognized by sera of sporozoite-immunized rodents, monkeys and human volunteers, as well as by naturally infected individuals[1,2]

  • Fine specificity of monoclonal antibody (MAB) derived from mice immunized with P. falciparum sporozoites

  • All of the MABs specific for minor repeats reacted with P. falciparum sporozoites by indirect immunofluorescence assay (IFA)

Read more

Summary

INTRODUCTION

The repeat region of the circumsporozoite (CS) protein of all Plasmodium species contains a species-specific immunodominant B cell epitope that is recognized by sera of sporozoite-immunized rodents, monkeys and human volunteers, as well as by naturally infected individuals[1,2]. Studies demonstrated that monoclonal antibody (MAB) specific for CS repeats derived from sporozoite-immunized experimental hosts were protective following passive transfer to susceptible rodents or monkeys. Passive transfer of 100–300 μg of human MAB specific for P. falciparum CS repeats, derived from volunteers immunized with the CS-based RTS,S vaccine, protected mice against challenge with transgenic P. berghei parasites expressing full length P. falciparum CS protein[8]. Differences in fine specificity of polyclonal antirepeat antibodies elicited in NANP peptide-immunized simian and rodent hosts were noted in early studies based on peptide ELISA and IFA reactivity with P. falciparum sporozoites[15,16]. Several MABs elicited by immunization with major repeats could be isolated, which did not have neutralizing activity These studies on fine specificity of sporozoite-neutralizing antibodies have important implications for vaccine design and analysis of functional humoral responses to the P. falciparum CS repeat region

RESULTS
DISCUSSION
METHODS
Ethics statement
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call